NCT04049630 (EOLoa) is a Phase 2 clinical trial of LEV 1 mg/kg in Onchocerciasis, Ocular, sponsored by Programme National de Lutte contre l'Onchocercose, Republic of the Congo.

Who is sponsoring NCT04049630?

NCT04049630 is sponsored by Programme National de Lutte contre l'Onchocercose, Republic of the Congo.

What drugs are being tested in NCT04049630?

Interventions in NCT04049630: LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg, Placebo.

What condition does NCT04049630 study?

NCT04049630 studies Onchocerciasis, Ocular, Loiasis.

Is NCT04049630 still recruiting?

NCT04049630 is currently completed. Last updated 20 September 2021.

Last reviewed 2021-09-20 · How we verify

NCT04049630: EOLoa

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

Completed Phase 2 Last updated 20 September 2021

What this trial tests

Phase 2 trial testing LEV 1 mg/kg in Onchocerciasis, Ocular in 255 participants. Completed in 15 July 2021.

Timeline

16 January 2021

Primary endpoint
24 April 2021

15 July 2021

Quick facts

Lead sponsor	Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	255
Start date	16 January 2021
Primary completion	24 April 2021
Estimated completion	15 July 2021
Sites	1 location across Republic of the Congo

Drugs / interventions tested

LEV 1 mg/kg — full drug profile →
LEV 1,5 mg/kg — full drug profile →
LEV 2,5 mg/kg — full drug profile →
Placebo

Conditions studied

Onchocerciasis, Ocular — all drugs for Onchocerciasis, Ocular →
Loiasis — all drugs for Loiasis →

Sponsor

Programme National de Lutte contre l'Onchocercose, Republic of the Congo — full company profile →

Who can join

Adults 18 to 65, any sex, with Onchocerciasis, Ocular or Loiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial.
Campillo JT, Bikita P, Hemilembolo M, Louya F, et al · · 2022 · cited 21× · PMID 34651190 · DOI 10.1093/cid/ciab906
Temporal variability of Loa loa microfilaraemia.
Campillo JT, Hemilembolo MC, Louya F, Bikita P, et al · · 2023 · cited 5× · PMID 36691079 · DOI 10.1186/s13071-022-05612-0
Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review.
Lotola Mougeni F, Bofill Roig M, Hübner MP, Klarmann-Schulz U, et al · · 2026 · PMID 41719376 · DOI 10.1371/journal.pntd.0013992

Verify or expand the search:

Other recruiting trials for Onchocerciasis, Ocular

Currently open trials in the same condition.

NCT06070116 — Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis · Phase 2 · active not recruiting

Other Programme National de Lutte contre l'Onchocercose, Republic of the Congo trials

Trials by the same sponsor.

NCT06613997 — 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia · Phase 3 · not yet recruiting
NCT06252961 — A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04049630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Last refreshed: 20 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04049630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing